CLAIMS

1. A pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt, having a weight- or a volume-based mean diameter that is no more than about 100 μm; and which particles are homogenously distributed within carrier particles having a weight- or a volume-based mean diameter that is within about ±75% of the relevant dimension of the solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration.

2. A dosage form according to Claim 1, in which the carrier particles comprise a physical mixture of materials selected from one or more carbohydrates, one or more pharmaceutically-acceptable inorganic salts and/or one or more pharmaceutically-acceptable substances that are insoluble or sparingly soluble in water.

3. A dosage form according to Claim 2, in which the one or more carbohydrates is/are selected from the group: sugars and sugar alcohols.

4. A dosage form according to Claim 3, in which the one or more sugars comprise lactose, and/or said one or more sugar alcohols is/are selected from the group: mannitol, sorbitol and xylitol.

5. A dosage form according to Claim 2, 3 or 4, in which the one or more pharmaceutically-acceptable inorganic salts comprise sodium chloride.

6. A dosage form according to any of Claims 2 to 5, in which the one or more pharmaceutically-acceptable substances that are insoluble or sparingly soluble in water is/are selected from the group: microcrystalline cellulose, dicalcium phosphate anhydrate, dicalcium phosphate dihydrate, tricalcium phosphate, calcium carbonate, barium sulphate, starch and pre-gelatinised starch.

7. A dosage form according to any preceding claim, in which the capsule is a hard-shell, two-piece capsule.

8. A dosage form according to Claim 7, in which the capsule is made from hydroxypropyl methylcellulose.

9. A dosage form according to any preceding claim, in which the particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butyl-thiophene-2-sulfonamide sodium salt have a weight- or a volume-based mean diameter that is no more than about 50 μm.

10. A dosage form according to Claim 9, in which the particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butyl-thiophene-2-sulfonamide sodium salt have a weight- or a volume-based mean diameter that is no more than about 20 μm.

11. A dosage form according to Claim 10, in which the particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butyl-thiophene-2-sulfonamide sodium salt have a weight- or a volume-based mean diameter that is no more than about 10 μm.

12. A dosage form according to any preceding claim, in which the carrier particle material comprises mannitol.

13. A dosage form according to any preceding claim, in which the glidant comprises a colloidal silica.

14. A dosage form according to any preceding claim, in which smaller particles of the glidant material coat the carrier particles.

15. A dosage form according to any preceding claim, which further comprises a lubricant.

16. A dosage form according to Claim 15, in which the lubricant is magnesium stearate.

17. A dosage form according to any preceding claim, that is essentially water-free.

18. A process for the production of a dosage form according to any preceding claim, which process comprises:

(a) mixing together the carrier particles and the glidant;

(b) mixing the blend from step (a) with particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethyl-phenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt; and

(c) loading the mixture from step (b) into a capsule that is suitable for peroral administration.

19. A process according to Claim 18, in which, prior to step (c), a lubricant according to Claim 15 or 16 is mixed together with the mixture from step (b).

20. A process according to Claim 18 or 19, in which the mixture from step (a), and/or step (b) (before and/or after adding the lubricant as appropriate) is passed through a sieve at least once in order to break up any agglomerates that are formed during the blending process.

21. A process according to Claim 20, in which at least one of sieving steps comprises passing through a sieve that is of a size of about 800 μm.

22. A dosage form obtainable by a process according to any of Claims 18 to 21.

23. A dosage form according to any of Claims 1 to 17 or 22 for use in the treatment of an interstitial lung disease.

24. Use of a dosage form according to any of Claims 1 to 17 or 22 for the manufacture of a medicament for the treatment of an interstitial lung disease.

25. A dosage form for use according to Claim 23 or use according to Claim 24, in which the interstitial lung disease is idiopathic pulmonary fibrosis.

26. A dosage form for use according to Claim 23 or use according to Claim 24, in which the interstitial lung disease is sarcoidosis.

27. A dosage form according to any of Claims 1 to 17 or 22 for use in the treatment of respiratory virus-induced tissue damage.

28. Use of a dosage form according to any of Claims 1 to 17 or 22 for the manufacture of a medicament for the treatment of respiratory virus-induced tissue damage.

29. A dosage form for use according to Claim 27 or use according to Claim 28, in which the damage comprises injury and/or dysfunction of the mucosal tissue of the respiratory tract that is caused by a respiratory virus.

30. A dosage form for use or use according to Claim 29, in which the respiratory virus is a coronavirus or is an influenza virus.

31. A dosage form for use or use according to Claim 29, in which the respiratory virus is severe acute respiratory syndrome coronavirus 2.

32. A dosage form for use or use according to any of Claims 27 to 31 (as appropriate), in which the treatment includes treatment of the symptoms of the disease that is being, or has been, caused by the virus.

33. A dosage form for use or use according to Claim 32, in which the symptoms of the damage or the disease include one or more of cough, dyspnea, respiratory distress, respiratory failure, pneumonia, fibrosis in one or more internal organs selected from the lungs, the heart and/or the kidneys.

34. A dosage form for use or use according to any of Claims 23 to 33 (as appropriate), in which the treatment includes prevention of morbidity and/or mortality in the relevant condition.

35. A dosage form for use or use according to any of Claims 23 to 34 (as appropriate), in which the composition is to be administered by the peroral route.